3	O
.	O
1	O
.	O

Glucose	O
Tolerance	O
Test	O
at	O
Various	O
Times	O
following	O
Dosing	O

DIO	O
mice	O
were	O
treated	O
with	O
a	O
single	O
IV	O
dose	O
of	O
CNTO	O
530	O
(	O
0	O
.	O
3	O
mg	O
/	O
kg	O
)	O
,	O
and	O
glucose	O
metabolism	O
was	O
monitored	O
using	O
an	O
intraperitoneal	B-Immaterial_anatomical_entity
glucose	O
tolerance	O
test	O
(	O
IPGTT	O
)	O
at	O
various	O
times	O
following	O
dosing	O
(	O
day	O
1	O
to	O
35	O
)	O
.	O

CNTO	O
530	O
did	O
not	O
influence	O
glucose	O
tolerance	O
24	O
hours	O
after	O
dosing	O
.	O

However	O
,	O
a	O
significant	O
improvement	O
was	O
observed	O
in	O
both	O
fasting	O
glucose	O
(	O
179	O
+	O
/	O
-	O
29	O
versus	O
133	O
+	O
/	O
-	O
19	O
mg	O
/	O
dL	O
for	O
untreated	O
versus	O
treated	O
)	O
and	O
overall	O
glucose	O
tolerance	O
seven	O
days	O
after	O
a	O
single	O
dose	O
of	O
CNTO	O
530	O
(	O
Figure	O
2	O
(	O
b	O
)	O
)	O
.	O

In	O
a	O
separate	O
study	O
,	O
the	O
activity	O
of	O
CNTO	O
530	O
was	O
compared	O
to	O
a	O
control	O
protein	O
that	O
lacked	O
the	O
EMP	O
-	O
1	O
peptides	O
to	O
ensure	O
that	O
the	O
observed	O
effects	O
were	O
due	O
to	O
the	O
peptide	O
and	O
not	O
the	O
Fc	O
.	O

The	O
glucose	O
lowering	O
effect	O
was	O
not	O
observed	O
in	O
the	O
mice	O
treated	O
with	O
the	O
protein	O
lacking	O
the	O
EMP	O
-	O
1	O
peptides	O
(	O
data	O
not	O
shown	O
)	O
.	O

Fasting	O
blood	B-Organism_substance
glucose	O
remained	O
improved	O
in	O
the	O
treated	O
animals	O
14	O
and	O
21	O
days	O
after	O
CNTO530	O
treatment	O
,	O
but	O
was	O
similar	O
to	O
the	O
untreated	O
group	O
after	O
35	O
days	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
for	O
the	O
glucose	O
tolerance	O
tests	O
showed	O
a	O
significant	O
improvement	O
with	O
CNTO	O
530	O
treatment	O
on	O
days	O
7	O
,	O
14	O
,	O
20	O
,	O
and	O
28	O
(	O
Figure	O
2	O
(	O
b	O
)	O
)	O
.	O

The	O
most	O
dramatic	O
effect	O
on	O
glucose	O
tolerance	O
following	O
CNTO	O
530	O
-	O
treatment	O
was	O
observed	O
on	O
day	O
14	O
where	O
glucose	O
was	O
cleared	O
from	O
circulation	O
by	O
the	O
15	O
-	O
minute	O
time	O
point	O
(	O
Figure	O
2	O
(	O
a	O
)	O
)	O
.	O

CNTO	O
530	O
-	O
mediated	O
acceleration	O
of	O
glucose	O
utilization	O
was	O
diminished	O
but	O
still	O
significant	O
by	O
day	O
28	O
and	O
not	O
seen	O
by	O
day	O
35	O
(	O
Figure	O
2	O
(	O
b	O
)	O
)	O
.	O

Hemoglobin	O
levels	O
followed	O
a	O
similar	O
time	O
-	O
dependent	O
change	O
,	O
showing	O
an	O
increase	O
that	O
peaked	O
on	O
day	O
22	O
and	O
returned	O
to	O
normal	O
levels	O
by	O
day	O
29	O
(	O
Figure	O
2	O
(	O
c	O
)	O
)	O
.	O

Similar	O
studies	O
were	O
completed	O
in	O
lean	O
littermate	O
mice	O
fed	O
a	O
normal	O
chow	O
diet	O
.	O

Mice	O
(	O
n	O
=	O
7	O
)	O
were	O
given	O
a	O
single	O
administration	O
of	O
CNTO	O
530	O
(	O
0	O
.	O
01	O
-	O
0	O
.	O
3	O
mg	O
/	O
kg	O
)	O
,	O
and	O
glucose	O
tolerance	O
tests	O
were	O
completed	O
after	O
1	O
and	O
14	O
days	O
.	O

As	O
we	O
observed	O
in	O
the	O
diabetic	O
rodents	O
,	O
no	O
significant	O
changes	O
were	O
seen	O
in	O
glucose	O
clearance	O
24	O
hours	O
after	O
dosing	O
.	O

However	O
,	O
there	O
were	O
significant	O
improvements	O
in	O
the	O
area	O
under	O
the	O
curve	O
in	O
the	O
glucose	O
tolerance	O
test	O
in	O
animals	O
dosed	O
with	O
0	O
.	O
3	O
and	O
0	O
.	O
1	O
mg	O
/	O
kg	O
CNTO	O
530	O
as	O
compared	O
to	O
PBS	O
(	O
22865	O
.	O
4	O
+	O
/	O
-	O
1900	O
.	O
2	O
,	O
24478	O
.	O
9	O
+	O
/	O
-	O
1093	O
.	O
4	O
,	O
and	O
28773	O
.	O
2	O
+	O
/	O
-	O
1368	O
.	O
3	O
,	O
resp	O
.	O
,	O
mean	O
+	O
/	O
-	O
SEM	O
)	O
.	O

There	O
were	O
no	O
dose	O
-	O
dependent	O
changes	O
in	O
the	O
fasting	O
blood	B-Organism_substance
glucose	O
.	O

